Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 934 entries
Sorted by: Best Match Show Resources per page
Pre-injury beta blocker use does not affect the hyperdynamic response in older trauma patients.

Journal of emergencies, trauma, and shock

Evans DC, Khoo KM, Radulescu A, Cook CH, Gerlach AT, Papadimos TJ, Steinberg SM, Stawicki SP, Eiferman DS.
PMID: 25400393
J Emerg Trauma Shock. 2014 Oct;7(4):305-9. doi: 10.4103/0974-2700.142766.

PURPOSE: Trauma dogma dictates that the physiologic response to injury is blunted by beta-blockers and other cardiac medications. We sought to determine how the pre-injury cardiac medication profile influences admission physiology and post-injury outcomes.MATERIALS AND METHODS: Trauma patients older...

Cite
Evans DC, Khoo KM, Radulescu A, et al. Pre-injury beta blocker use does not affect the hyperdynamic response in older trauma patients. J Emerg Trauma Shock. 2014;7(4):305-9doi: 10.4103/0974-2700.142766.
Evans, D. C., Khoo, K. M., Radulescu, A., Cook, C. H., Gerlach, A. T., Papadimos, T. J., Steinberg, S. M., Stawicki, S. P., & Eiferman, D. S. (2014). Pre-injury beta blocker use does not affect the hyperdynamic response in older trauma patients. Journal of emergencies, trauma, and shock, 7(4), 305-9. https://doi.org/10.4103/0974-2700.142766
Evans, David C, et al. "Pre-injury beta blocker use does not affect the hyperdynamic response in older trauma patients." Journal of emergencies, trauma, and shock vol. 7,4 (2014): 305-9. doi: https://doi.org/10.4103/0974-2700.142766
Evans DC, Khoo KM, Radulescu A, Cook CH, Gerlach AT, Papadimos TJ, Steinberg SM, Stawicki SP, Eiferman DS. Pre-injury beta blocker use does not affect the hyperdynamic response in older trauma patients. J Emerg Trauma Shock. 2014 Oct;7(4):305-9. doi: 10.4103/0974-2700.142766. PMID: 25400393; PMCID: PMC4231268.
Copy Download .nbib Format: NLM
The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine.

International journal of cardiovascular research

Jang D, Donovan S, Bania T, Nelson L, Hoffman R, Chu J.
PMID: 24416727
Int J Cardiovasc Res. 2013 Mar 29;2(2):1000121.

BACKGROUND: Cardiovascular drug poisoning remains a leading cause of fatality. Within this class, calcium channel blockers (CCBs) account for the majority of deaths. CCBs are typically categorized as dihydropyridines (i.e. amlodipine or nifedipine) versus the non-dihydropyridine (i.e. verapamil and...

Cite
Jang D, Donovan S, Bania T, et al. The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine. Int J Cardiovasc Res. 2013;2(2):1000121
Jang, D., Donovan, S., Bania, T., Nelson, L., Hoffman, R., & Chu, J. (2013). The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine. International journal of cardiovascular research, 2(2), 1000121.
Jang, David, et al. "The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine." International journal of cardiovascular research vol. 2,2 (2013): 1000121.
Jang D, Donovan S, Bania T, Nelson L, Hoffman R, Chu J. The Novel Development of an Experimental Model of Dihydropyridine Calcium Channel Blocker Poisoning using Intravenous Amlodipine. Int J Cardiovasc Res. 2013 Mar 29;2(2):1000121. PMID: 24416727; PMCID: PMC3886834.
Copy Download .nbib Format: NLM
A double-blind comparative study of clinical efficacy of verapamil versus lithium in acute mania.

International journal of psychiatry in clinical practice

Pal Singh G.
PMID: 24937719
Int J Psychiatry Clin Pract. 2008;12(4):303-8. doi: 10.1080/13651500802209670.

Objectives. The importance of intracellular calcium ions to processes that may be involved in mania and the calcium antagonist action of mood stabilizers suggest a role of verapamil in the treatment of mania. This study was undertaken to compare...

Cite
Pal Singh G. A double-blind comparative study of clinical efficacy of verapamil versus lithium in acute mania. Int J Psychiatry Clin Pract. 2008;12(4):303-8doi: 10.1080/13651500802209670.
Pal Singh, G. (2008). A double-blind comparative study of clinical efficacy of verapamil versus lithium in acute mania. International journal of psychiatry in clinical practice, 12(4), 303-8. https://doi.org/10.1080/13651500802209670
Pal Singh, Gurvinder. "A double-blind comparative study of clinical efficacy of verapamil versus lithium in acute mania." International journal of psychiatry in clinical practice vol. 12,4 (2008): 303-8. doi: https://doi.org/10.1080/13651500802209670
Pal Singh G. A double-blind comparative study of clinical efficacy of verapamil versus lithium in acute mania. Int J Psychiatry Clin Pract. 2008;12(4):303-8. doi: 10.1080/13651500802209670. PMID: 24937719.
Copy Download .nbib Format: NLM
Use of Calcium Channel Blockers in Serbia in the Period from 2008 to 2012 Year.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Milijasevic D, Tomic N, Milijasevic B, Vukmirovic S, Raskovic A, Tomic Z.
PMID: 27202765
Value Health. 2014 Nov;17(7):A758. doi: 10.1016/j.jval.2014.08.244. Epub 2014 Oct 26.

No abstract available.

Cite
Milijasevic D, Tomic N, Milijasevic B, et al. Use of Calcium Channel Blockers in Serbia in the Period from 2008 to 2012 Year. Value Health. 2014;17(7):A758doi: 10.1016/j.jval.2014.08.244.
Milijasevic, D., Tomic, N., Milijasevic, B., Vukmirovic, S., Raskovic, A., & Tomic, Z. (2014). Use of Calcium Channel Blockers in Serbia in the Period from 2008 to 2012 Year. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A758. https://doi.org/10.1016/j.jval.2014.08.244
Milijasevic, D, et al. "Use of Calcium Channel Blockers in Serbia in the Period from 2008 to 2012 Year." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A758. doi: https://doi.org/10.1016/j.jval.2014.08.244
Milijasevic D, Tomic N, Milijasevic B, Vukmirovic S, Raskovic A, Tomic Z. Use of Calcium Channel Blockers in Serbia in the Period from 2008 to 2012 Year. Value Health. 2014 Nov;17(7):A758. doi: 10.1016/j.jval.2014.08.244. Epub 2014 Oct 26. PMID: 27202765.
Copy Download .nbib Format: NLM
A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Fang CH, Lin KY, Huang YC, Liu L.
PMID: 27202782
Value Health. 2014 Nov;17(7):A761-2. doi: 10.1016/j.jval.2014.08.263. Epub 2014 Oct 26.

No abstract available.

Cite
Fang CH, Lin KY, Huang YC, et al. A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan. Value Health. 2014;17(7):A761-2doi: 10.1016/j.jval.2014.08.263.
Fang, C. H., Lin, K. Y., Huang, Y. C., & Liu, L. (2014). A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A761-2. https://doi.org/10.1016/j.jval.2014.08.263
Fang, C H, et al. "A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A761-2. doi: https://doi.org/10.1016/j.jval.2014.08.263
Fang CH, Lin KY, Huang YC, Liu L. A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan. Value Health. 2014 Nov;17(7):A761-2. doi: 10.1016/j.jval.2014.08.263. Epub 2014 Oct 26. PMID: 27202782.
Copy Download .nbib Format: NLM
Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions.

Experimental and therapeutic medicine

Hotta S, Nakatani Y, Kambe T, Abe K, Masuda Y, Utsumomiya I, Taguchi K.
PMID: 26622350
Exp Ther Med. 2015 Aug;10(2):535-540. doi: 10.3892/etm.2015.2575. Epub 2015 Jun 12.

Guillain-Barré syndrome is a type of acute inflammatory neuropathy that causes ataxia and is associated with the IgG anti-GM1 antibody. However, the pathogenic role of the IgG anti-GM1 antibody and calcium channels in neuromuscular junctions (NMJs) remains unclear. Thus,...

Cite
Hotta S, Nakatani Y, Kambe T, et al. Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions. Exp Ther Med. 2015;10(2):535-540doi: 10.3892/etm.2015.2575.
Hotta, S., Nakatani, Y., Kambe, T., Abe, K., Masuda, Y., Utsumomiya, I., & Taguchi, K. (2015). Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions. Experimental and therapeutic medicine, 10(2), 535-540. https://doi.org/10.3892/etm.2015.2575
Hotta, Sayako, et al. "Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions." Experimental and therapeutic medicine vol. 10,2 (2015): 535-540. doi: https://doi.org/10.3892/etm.2015.2575
Hotta S, Nakatani Y, Kambe T, Abe K, Masuda Y, Utsumomiya I, Taguchi K. Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions. Exp Ther Med. 2015 Aug;10(2):535-540. doi: 10.3892/etm.2015.2575. Epub 2015 Jun 12. PMID: 26622350; PMCID: PMC4509117.
Copy Download .nbib Format: NLM
Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases.

Cardiology and therapy

Rodríguez Padial L, Barón-Esquivias G, Hernández Madrid A, Marzal Martín D, Pallarés-Carratalá V, de la Sierra A.
PMID: 27016085
Cardiol Ther. 2016 Jun;5(1):75-82. doi: 10.1007/s40119-016-0059-1. Epub 2016 Mar 25.

UNLABELLED: Cardiovascular diseases are the leading cause of death in the world. Coronary artery diseases, atrial fibrillation or hypertensive heart disease, are among the most important cardiovascular disorders. Hypertension represents a significant risk factor for cardiovascular mortality; thus, control...

Cite
Rodríguez Padial L, Barón-Esquivias G, Hernández Madrid A, et al. Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases. Cardiol Ther. 2016;5(1):75-82doi: 10.1007/s40119-016-0059-1.
Rodríguez Padial, L., Barón-Esquivias, G., Hernández Madrid, A., Marzal Martín, D., Pallarés-Carratalá, V., & de la Sierra, A. (2016). Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases. Cardiology and therapy, 5(1), 75-82. https://doi.org/10.1007/s40119-016-0059-1
Rodríguez Padial, Luis, et al. "Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases." Cardiology and therapy vol. 5,1 (2016): 75-82. doi: https://doi.org/10.1007/s40119-016-0059-1
Rodríguez Padial L, Barón-Esquivias G, Hernández Madrid A, Marzal Martín D, Pallarés-Carratalá V, de la Sierra A. Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases. Cardiol Ther. 2016 Jun;5(1):75-82. doi: 10.1007/s40119-016-0059-1. Epub 2016 Mar 25. PMID: 27016085; PMCID: PMC4906086.
Copy Download .nbib Format: NLM
Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies.

Journal of neurodegenerative diseases

Mullapudi A, Gudala K, Boya CS, Bansal D.
PMID: 27516917
J Neurodegener Dis. 2016;2016:5780809. doi: 10.1155/2016/5780809. Epub 2016 Jul 19.

Background. Antihypertensive agents have been shown to inhibit oxidative stress and inflammatory response and thus neuroprotection in Parkinson's disease (PD). Epidemiological evidence suggests inconsistency between use of antihypertensives and risk of PD. This study is aimed to examine the...

Cite
Mullapudi A, Gudala K, Boya CS, et al. Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies. J Neurodegener Dis. 2016;2016:5780809doi: 10.1155/2016/5780809.
Mullapudi, A., Gudala, K., Boya, C. S., & Bansal, D. (2016). Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies. Journal of neurodegenerative diseases, 20165780809. https://doi.org/10.1155/2016/5780809
Mullapudi, Amarnath, et al. "Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies." Journal of neurodegenerative diseases vol. 2016 (2016): 5780809. doi: https://doi.org/10.1155/2016/5780809
Mullapudi A, Gudala K, Boya CS, Bansal D. Risk of Parkinson's Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies. J Neurodegener Dis. 2016;2016:5780809. doi: 10.1155/2016/5780809. Epub 2016 Jul 19. PMID: 27516917; PMCID: PMC4969534.
Copy Download .nbib Format: NLM
A Case Study of Severe Esophageal Dysmotility following Laparoscopic Sleeve Gastrectomy.

Case reports in surgery

Sheppard CE, Sadowski DC, Gill R, Birch DW.
PMID: 27413570
Case Rep Surg. 2016;2016:9363545. doi: 10.1155/2016/9363545. Epub 2016 Jun 19.

Following bariatric surgery, a proportion of patients have been observed to experience reflux, dysphagia, and/or odynophagia. The etiology of this constellation of symptoms has not been systematically studied to date. This case describes a 36-year-old female with severe esophageal...

Cite
Sheppard CE, Sadowski DC, Gill R, et al. A Case Study of Severe Esophageal Dysmotility following Laparoscopic Sleeve Gastrectomy. Case Rep Surg. 2016;2016:9363545doi: 10.1155/2016/9363545.
Sheppard, C. E., Sadowski, D. C., Gill, R., & Birch, D. W. (2016). A Case Study of Severe Esophageal Dysmotility following Laparoscopic Sleeve Gastrectomy. Case reports in surgery, 20169363545. https://doi.org/10.1155/2016/9363545
Sheppard, Caroline E, et al. "A Case Study of Severe Esophageal Dysmotility following Laparoscopic Sleeve Gastrectomy." Case reports in surgery vol. 2016 (2016): 9363545. doi: https://doi.org/10.1155/2016/9363545
Sheppard CE, Sadowski DC, Gill R, Birch DW. A Case Study of Severe Esophageal Dysmotility following Laparoscopic Sleeve Gastrectomy. Case Rep Surg. 2016;2016:9363545. doi: 10.1155/2016/9363545. Epub 2016 Jun 19. PMID: 27413570; PMCID: PMC4930820.
Copy Download .nbib Format: NLM
IP3R and RyR calcium channels are involved in neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α.

American journal of translational research

Wang GJ, Guo LY, Wang HX, Yao YS.
PMID: 28337264
Am J Transl Res. 2017 Feb 15;9(2):343-354. eCollection 2017.

To investigate which calcium channels are involved in cardiac myocyte hypertrophy induced by TNF-α, cultured cardiomyocytes were treated with 100 μg/L TNF-α. In addition, three different calcium channel blockers (2-APB, ryanodine and nifedipine) were used, and the effects of...

Cite
Wang GJ, Guo LY, Wang HX, et al. IP3R and RyR calcium channels are involved in neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α. Am J Transl Res. 2017;9(2):343-354
Wang, G. J., Guo, L. Y., Wang, H. X., & Yao, Y. S. (2017). IP3R and RyR calcium channels are involved in neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α. American journal of translational research, 9(2), 343-354.
Wang, Gui-Jun, et al. "IP3R and RyR calcium channels are involved in neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α." American journal of translational research vol. 9,2 (2017): 343-354.
Wang GJ, Guo LY, Wang HX, Yao YS. IP3R and RyR calcium channels are involved in neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α. Am J Transl Res. 2017 Feb 15;9(2):343-354. eCollection 2017. PMID: 28337264; PMCID: PMC5340671.
Copy Download .nbib Format: NLM
Management of Hypertension Using Olmesartan Alone or in Combination.

Cardiology and therapy

Zhang X, Zhang H, Ma Y, Che W, Hamblin MR.
PMID: 28258390
Cardiol Ther. 2017 Jun;6(1):13-32. doi: 10.1007/s40119-017-0087-5. Epub 2017 Mar 03.

Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the...

Cite
Zhang X, Zhang H, Ma Y, et al. Management of Hypertension Using Olmesartan Alone or in Combination. Cardiol Ther. 2017;6(1):13-32doi: 10.1007/s40119-017-0087-5.
Zhang, X., Zhang, H., Ma, Y., Che, W., & Hamblin, M. R. (2017). Management of Hypertension Using Olmesartan Alone or in Combination. Cardiology and therapy, 6(1), 13-32. https://doi.org/10.1007/s40119-017-0087-5
Zhang, Xiaoshen, et al. "Management of Hypertension Using Olmesartan Alone or in Combination." Cardiology and therapy vol. 6,1 (2017): 13-32. doi: https://doi.org/10.1007/s40119-017-0087-5
Zhang X, Zhang H, Ma Y, Che W, Hamblin MR. Management of Hypertension Using Olmesartan Alone or in Combination. Cardiol Ther. 2017 Jun;6(1):13-32. doi: 10.1007/s40119-017-0087-5. Epub 2017 Mar 03. PMID: 28258390; PMCID: PMC5446820.
Copy Download .nbib Format: NLM
Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial.

Emergency (Tehran, Iran)

Shojaee M, Feizi B, Miri R, Etemadi J, Feizi AH.
PMID: 28286836
Emerg (Tehran). 2017;5(1):e29. Epub 2017 Jan 10.

INTRODUCTION: Treatment of rapid ventricular response arterial fibrillation (rapid AF) varies depending on the decision of the in-charge physician, condition of the patient, availability of the drug, and the treatment protocol of the hospital. The present study was designed...

Cite
Shojaee M, Feizi B, Miri R, et al. Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Emerg (Tehran). 2017;5(1):e29
Shojaee, M., Feizi, B., Miri, R., Etemadi, J., & Feizi, A. H. (2017). Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Emergency (Tehran, Iran), 5(1), e29.
Shojaee, Majid, et al. "Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial." Emergency (Tehran, Iran) vol. 5,1 (2017): e29.
Shojaee M, Feizi B, Miri R, Etemadi J, Feizi AH. Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial. Emerg (Tehran). 2017;5(1):e29. Epub 2017 Jan 10. PMID: 28286836; PMCID: PMC5325898.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 934 entries